| GTO ID | GTC3799 |
| Trial ID | NCT06307431 |
| Disease | Breast Cancer | Colorectal Cancer | Renal Cell Carcinoma | Sarcoma | Malignant Mesothelioma | Glioblastoma |
| Therapy | mRNA vaccine |
| Treatment | V940|mRNA-4157 |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma |
| Year | 2024 |
| Country | United States |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V940-004|2023-505177-32 |
| Vector information | |||
|
|||
| Cohort1: V940 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||